Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Feb 1, 2029 → Jun 1, 2029
See other at-risk trials from University of California, San Francisco

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 1, 2026 to Dec 15, 2026 Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion pushed from Feb 1, 2029 to Jun 1, 2029
    • Study completion pushed from Feb 1, 2030 to Jun 1, 2030
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.
Trial Details
NCT Number NCT07682454
Lead Sponsor University of California, San Francisco
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Related terms Carcinoma, Hepatocellular
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov